Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document. Clinical guidance is as of August 6, 2008 and financial guidance relating to the Company's current cash, cash equivalents and investments is as of June 30, 2008.

This press release includes forward-looking statements regarding the development of the Company's product can
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... LAWRENCEVILLE, N.J. , Aug. 3, 2015 /PRNewswire/ ... that the Company will host a conference call ... and provide an update on its development programs ... doxorubicin, and two newly acquired technology platforms, TheraPlas™ ... 11:00 a.m. EDT on Monday, August 10, 2015. ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4
... YORK,  June 6, 2011 Aeolus Pharmaceuticals, Inc. (OTCQB: ... is available for on-demand viewing. LINK: ... button. Aeolus Pharmaceuticals, presentation will be available ... the "virtual trade booth" for the next three weeks. ...
... NEW YORK, June 6, 2011 Reportlinker.com ... is available in its catalogue: ... and Companies http://www.reportlinker.com/p0350370/Transdermal-Drug-Delivery---Technologies-Markets-and-Companies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... report * Up-to-date one-stop ...
Cached Medicine Technology:Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2Transdermal Drug Delivery - Technologies, Markets, and Companies 2
(Date:8/3/2015)... Scottsdale, AZ (PRWEB) , ... ... ... Services, Inc. (EMSI), a leading provider of medical information, risk management and ... the company’s evolution and direction toward focused, expert information solutions that improve ...
(Date:8/3/2015)... ... ... Did you know that there are thousands of Seniors or Elderly ... options which A-1 Home Care Agency specialize in? In fact, diversity, multi-cultural, financing options, ... Care Agency is known for. , With all the Los Angeles ...
(Date:8/2/2015)... ... 03, 2015 , ... Career Step, an online institution offering ... for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, on Friday ... AHDI conference provides us to interact with those in the healthcare documentation industry,” ...
(Date:8/2/2015)... ... , ... For many “would be” entrepreneurs, starting a new business can prove to be ... start a business.” Neither needs be a major obstacle. , The U.S. has always ... business and be successful. The risks of starting a business can be high but the ...
(Date:8/2/2015)... ... 2015 , ... Molecular biologists in New South Wales say a protein linked ... just posted an article on the new research. Click here to read it ... expression in tissue samples from 42 patients with peritoneal mesothelioma and found a direct ...
Breaking Medicine News(10 mins):Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... Special Appearances Planned by Molar Man! , ... Glendale, AZ (Vocus) February ... Dental of Arizona Foundation,s Dental Health Month at the Children,s Museum of ... as National Children,s Dental Health Month, Delta Dental of Arizona Foundation will ...
... Compass Pharma Services LLC is offering contract pharmaceutical ... blister packages and diagnostic medical devices. For maximum ... operates 20 production suites on a two-shift-per-day schedule ... into virtually all packaging forms including blister packages, ...
... Feb. 10 The University HealthSystem Consortium (UHC) ... with Cartus Corporation, a provider of relocation services ... 2 optional 1-year renewal periods, is effective as ... counseling, expense administration, home sale assistance programs, moving ...
... CatalogST. LOUIS, Feb. 10 SAFC Supply Solutions(R), a ... Group (Nasdaq: SIAL ) , and ... that it has added 50 new Certified Organics products ... line. Details of the new products are available ...
... Calif., Feb. 9 Varian, Inc.,(NasdaqGS: VARI) today reported that ... President and Chief Executive Officer, as Chairman,of the Board. ... upon,expiration of his director term at the annual meeting of ... the company,s Chief Executive,Officer. , "We ...
... the rising cost of health care, more and more ... care. During National Wise Health Consumer Month , ... take another look at chiropractic care.February is National ... time for Minnesotans to learn about chiropractic care and ...
Cached Medicine News:Health News:Children's Museum of Phoenix & Delta Dental of Arizona Foundation Celebrate National Children's Dental Health Month 2Health News:Children's Museum of Phoenix & Delta Dental of Arizona Foundation Celebrate National Children's Dental Health Month 3Health News:Children's Museum of Phoenix & Delta Dental of Arizona Foundation Celebrate National Children's Dental Health Month 4Health News:Compass Pharma Services Offers Microfill Capabilities to Contract Pharmaceutical Packaging Customers 2Health News:University HealthSystem Consortium Selects Cartus to Provide Relocation Services 2Health News:SAFC Supply Solutions Introduces Certified Organics to Flavors & Fragrances Product Line 2Health News:SAFC Supply Solutions Introduces Certified Organics to Flavors & Fragrances Product Line 3Health News:SAFC Supply Solutions Introduces Certified Organics to Flavors & Fragrances Product Line 4Health News:Garry W. Rogerson Elected Chairman of the Board of Varian, Inc. 2Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 2Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 3Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 4Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 5
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: